- Home
- KRAQ vs ALT Comparison
KRAQ vs ALT Comparison
Compare KRAQ & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KRAQ | ALT |
|---|---|---|
| Founded | 2025 | 1997 |
| Country | United States | United States |
| Employees | 2 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 427.8M | 421.5M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | KRAQ | ALT |
|---|---|---|
| Price | $9.97 | $2.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 66.2K | ★ 3.2M |
| Earning Date | N/A | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $9.78 | $2.56 |
| 52 Week High | $9.99 | $7.73 |
Technical Indicators
Market Signals| Indicator | KRAQ | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 72.88 | 55.14 |
| Support Level | $9.87 | $2.87 |
| Resistance Level | N/A | $3.20 |
| Average True Range (ATR) | 0.01 | 0.12 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 100.00 | 72.37 |
Price Performance
Historical ComparisonAbout KRAQ KRAKacquisition Corp Class A Ordinary Shares
Krakacquisition Corp is a blank check company formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About ALT Altimmune Inc.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.